(4-pyridyl)methyl hydrazine dihydrochloride | 89598-56-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (4-pyridyl)methyl hydrazine dihydrochloride
• 英文别名: 2-((Pyridin-4-yl)methyl)hydrazine hydrochloride；pyridin-4-ylmethylhydrazine;hydrochloride
• CAS: 89598-56-1
• 化学式: C₆H₉N₃*2ClH
• 分子量: 196.079
• InChiKey: MNRWHUKMYOKCMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.47
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  50.9
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312+P330,P302+P352+P312,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P363,P403+P233,P405,P501
• 危险性描述：
  H302,H312,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  (4-pyridyl)methyl hydrazine dihydrochloride 在 chloro-N,N,N',N'-bis(tetramethylene)formamidinium hexafluorophosphate 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.08h， 生成 C₁₈H₁₆ClFN₄O
  参考文献：
  名称：

  Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel Activators

  摘要：

  The G protein-gated inwardly-rectifying potassium channels (GIRK, KO) are a family of inward-rectifying potassium channels, and there is significant evidence supporting the roles of GIRKs in a number of physiological processes and as potential targets for numerous indications. Previously reported urea containing molecules as GIRK1/2 preferring activators have had significant pharmacokinetic (PK) liabilities. Here we report a novel series of 1H-pyrazolo-5yl-2-phenylacetamides in an effort to improve upon the PK properties. This series of compounds display nanomolar potency as GIRK1/2 activators with improved brain distribution (rodent K-p > 0.6).

  DOI：

  10.1021/acschemneuro.7b00217
• 作为产物：
  描述：

  (tert-butoxy)-N-[(4-pyridylmethyl)amino]carboxamide 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 以6.5 g的产率得到(4-pyridyl)methyl hydrazine dihydrochloride
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIMIDINES AS INHIBITORS OF GLUCOCORTICOID RECEPTOR TRANSLOCATION
  [FR] PYRAZOLOPYRIMIDINES UTILISÉES EN TANT QU'INHIBITEURS DE LA TRANSLOCATION DU RÉCEPTEUR DES GLUCOCORTICOÏDES

  摘要：

  公开号：

  WO2016123392A3

文献信息

• [EN] PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDAZINONE ET LEUR UTILISATION COMME INHIBITEURS DU RÉCEPTEUR P2X7
  申请人：NISSAN CHEMICAL IND LTD

  公开号：WO2009057827A1

  公开（公告）日：2009-05-07

  Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.

  翻译结果为：新型的哒嗪酮化合物，其化学公式为(I)，能够抑制嘌呤能P2X7受体，并对预防、治疗和改善炎症性和免疫性疾病有益。
• Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
  申请人：Novartis AG

  公开号：US06465504B1

  公开（公告）日：2002-10-15

  The use is described of 3,5-diphenyl-1,2,4-triazoles of the formula I in which R1-R5 are as defined in the description. The compounds have useful pharmaceutical properties and are particularly active as iron chelators. They can be used for the treatment of iron overload in warm-blooded animals.

  本文描述了公式I中的3,5-二苯基-1,2,4-三唑的用途，其中R1-R5如描述所定义。这些化合物具有有用的药理特性，特别是作为铁螯合剂具有很高的活性。它们可以用于治疗温血动物中的铁过载。
• SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
  申请人：Nura Bio, Inc.

  公开号：US20220081417A1

  公开（公告）日：2022-03-17

  This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological diseases.

  本公开涉及替代吡啶化合物和组合物，以及相关方法，用于抑制SARM1活性和/或用于治疗或预防神经系统疾病。
• PYRAZOLYLBENZENE-1,3-DIOLS FOR DISEASES ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 18 AND IN COMBINATION WITH TRANSIENT RECEPTOR POTENTIAL VANILLOID 1
  申请人：Temple University-Of The Commonwealth System of Higher Education

  公开号：US20210323927A1

  公开（公告）日：2021-10-21

  The present invention relates to pyrazolylbenzene-1,3-diols as cannabidiol derivatives, its use for the manufacture of a medicament, and more particularly, to the use of this medicament for the treatment and/or prevention of a disorder associated with the GPR18 and/or TRPV1 receptors and the use of these compounds for pharmacological assays related to GPR18 and/or TRPV1.

  本发明涉及吡唑基苯-1,3-二酚作为大麻二酚衍生物，其用于制造药物，并更具体地，用于治疗和/或预防与GPR18和/或TRPV1受体相关的疾病的药物的使用，以及利用这些化合物进行与GPR18和/或TRPV1相关的药理学测定的用途。
• Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73
  作者：Joel W. Beatty、Erick A. Lindsey、Rhiannon Thomas-Tran、Laurent Debien、Debashis Mandal、Jenna L. Jeffrey、Anh T. Tran、Jeremy Fournier、Steven D. Jacob、Xuelei Yan、Samuel L. Drew、Elaine Ginn、Ada Chen、Amber T. Pham、Sharon Zhao、Lixia Jin、Stephen W. Young、Nigel P. Walker、Manmohan Reddy Leleti、Susanne Moschütz、Norbert Sträter、Jay P. Powers、Kenneth V. Lawson

  DOI：10.1021/acs.jmedchem.9b01713

  日期：2020.4.23

  Traditional efforts to inhibit CD73 have involved antibody therapy or the development of small molecules, the most potent of which mimic the acidic and ionizable structure of the enzyme's natural substrate, adenosine 5'-monophosphate (AMP). Here, we report the systematic discovery of a novel class of non-nucleotide CD73 inhibitors that are more potent than all other nonphosphonate inhibitor classes reported

  CD73是嘌呤能信号传导的细胞外介质。当在肿瘤微环境中上调时，CD73已通过腺苷的过量产生而牵涉抑制免疫功能。抑制CD73的传统努力涉及抗体疗法或小分子的发展，其中最有效的模仿酶天然底物的酸性和可离子化结构的5'-单磷酸腺苷（AMP）。在这里，我们报告了一种新型的非核苷酸CD73抑制剂的系统发现，该抑制剂比迄今报道的所有其他非膦酸酯抑制剂类更有效。这些努力最终导致发现了4-（5- [4-氟-1-（2H-吲唑-6-基）-1H-1,2,3-苯并三唑-6-基] -1H-吡唑- 1-基}甲基）苄腈（73，IC50 = 12 nM）和4-（5- [4-氯-1-（2H-吲唑-6-基）-1H-1,2，3-苯并三唑-6-基] -1H-吡唑-1-基}甲基）苄腈（74，IC50 = 19 nM）。74与人CD73的共结晶显示出竞争性结合模式。这些化合物显示出通过降低已知的CD73核苷抑制剂固有的酸度和低膜渗透性来改善类药物特性的希望。